Government-Owned Inventions; Availability for Licensing, 11215-11216 [06-2098]

Download as PDF Federal Register / Vol. 71, No. 43 / Monday, March 6, 2006 / Notices commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. at least one peptide within P450 2D6 that were recognized by HLA– DRB*0301-restricted T cells. The technology is partially described in Hepatology 2005; 42: 291A–292A. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. Methods for Rapid and Specific Fluorescent Staining of Biological Tissue for Laser Capture Microdissection Robert A. Star (NIDDK), Hiroshi Murakami (NIDDK), Lance A. Liotta (NCI), Kenneth R. Spring (NHLBI) U.S. Patent No. 6,790,636 issued 14 Sep 2004 (HHS Reference No. E–133– 2000/0–US–02). Licensing Contact: Michael Shmilovich; 301–435–5019; shmilovm@mail.nih.gov. Available for licensing and commercial development are methods for rapid and specific fluorescent staining of biological tissue samples that substantially preserve biological molecules such as mRNA. Also within the scope of the invention are methods for microdissecting tissue to obtain pure populations of cells or tissue structures based upon identifying and excising cells or tissue structures that are labeled with fluorescent specific binding agents. A laser capture microdissection (LCM) apparatus useful for identifying and isolating cells and tissue structures following rapid immunofluorescent staining is also disclosed. Other LCM devices are available for purchase from Arcturus Engineering. Dated: February 27, 2006. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 06–2097 Filed 3–3–06; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. hsrobinson on PROD1PC70 with NOTICES AGENCY: SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious VerDate Aug<31>2005 14:30 Mar 03, 2006 Jkt 208001 Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. ADDRESSES: Deoxyhypusine Hydroxylase Myung Hee Park et al. (NIDCR) U.S. Provisional Application No. 60/ 748,879 filed 09 Dec 2005 (HHS Reference No. E–051–2006/0–US–01). Licensing Contact: John Stansberry; 301/ 435–5236; stansbej@mail.nih.gov. Translation initiation factor eIF5A is a highly conserved eukaryotic protein. One of its lysine residues is enzymatically modified, using spermidine, to form an unusual amino acid, hypusine, a posttranslational modification unique to eIF–5A. This eukaryotic initiation factor (eIF5A) and its hypusine modification are essential for mammalian cell proliferation. Inventors at the National Institutes of Health have recently cloned and characterized the enzyme deoxyhypusine hydroxylase (DOHH) that catalyzes the final step in the modification of eIF5A. The inventors have characterized and cloned both the yeast and human recombinant versions of this enzyme. Studies have shown that metal chelating compounds like deferiprone and ciclopirox olamine that inhibit DOHH activity in cells also inhibit HIV– 1 replication in cell culture. These findings suggest potential utility of DOHH as a novel target for anti-cancer and anti-retroviral therapy. These advances could also conceivably lead to the development of small molecule inhibitors that bind to specific sites in the enzyme. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 11215 Methods of Treating Cancer Using Pyridine Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents Philip J. Tofilon et al. (NCI) U.S. Provisional Application No. 60/ 718,172 filed 16 Sep 2005 (HHS Ref. No. E–319–2005/0–US–01). Licensing Contact: George G. Pipia; 301/ 435–5560; pipiag@mail.nih.gov. Ribonucleotide reductase is the ratelimiting enzyme of de novo DNA synthesis. The enzyme is composed of two homodimer subunits, hRRM1 and hRRM2. Hydroxyurea, a ribonucleotide reductase inhibitor, is commonly used in conjunction with radiotherapy but it its efficacy as shown in many chemoradiation trials is limited. Triapine (2-carboxyaldehyde pyridine thiosemicarbazone), a novel ribonucleotide reductase inhibitor, exhibits sensitivity to the subunit hRRM2 and inhibits ribonucleotide reductase more effectively when compared to hydroxyurea, thus imparting a radiosensitizing effect. This present invention provides methods of preventing DNA synthesis and DNA repair after exposing cells to ionizing radiation. The present invention further provides methods of treating cancer and other tumors by coadministration of a radiosensitizing amount of Triapine and ionizing radiation. Methods and Compositions for Treating FUS1 Related Disorders Michael I. Lerman et al. (NCI) U.S. Provisional Application No. 60/ 697,596 filed 07 Jul 2005 (HHS Reference No. E–137–2005/0–US–01). Licensing Contact: Thomas Clouse; 301/ 435–4076; clousetp@mail.nih.gov. The FUS1 gene residing in the 3p21.3 chromosome region may function as a tumor suppressor gene. Results show that FUS1 null mutants show consistent changes in NK cells and secreted antibodies, suggesting that FUS1 plays an important role in the development and activation of the mammalian immune system. The invention relates to methods, systems and transgenic animals useful for screening, diagnosing and treating FUS1 related disorders. Interestingly, targeted disruption of FUS1 gene in mice resulted in a viable and fertile phenotype. Possible uses of this invention include using the FUS1 protein to modulate and boost the immune system in diseases like cancer and AIDS. Also, the cDNA and the corresponding protein are small and the applications could include gene therapy with E:\FR\FM\06MRN1.SGM 06MRN1 11216 Federal Register / Vol. 71, No. 43 / Monday, March 6, 2006 / Notices appropriate vectors and protein transduction technology. Dated: February 28, 2006. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 06–2098 Filed 3–3–06; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Coast Guard DEPARTMENT OF TRANSPORTATION Maritime Administration [USCG–2005–21232] Beacon Port Liquefied Natural Gas Deepwater Port License Application; Draft Environmental Impact Statement Coast Guard, DHS; Maritime Administration, DOT. ACTION: Notice of availability; notice of public meeting; request for comments. hsrobinson on PROD1PC70 with NOTICES AGENCY: SUMMARY: The Coast Guard and the Maritime Administration (MARAD) announce the availability of the draft environmental impact statement (DEIS) for this license application. The application describes a project that would be located in the Gulf of Mexico, in lease block High Island Area 27, on the outer Continental Shelf (OCS). The Main Terminal would be located approximately 45 miles South of High Island and 50 miles East-Southeast of Galveston, Texas, with a riser platform in lease block West Cameron 167, approximately 27 miles South of Holly Beach and 29 miles South-Southeast of Johnson’s Bayou, Louisiana. The Coast Guard and MARAD request public comments on the DEIS. DATES: The public meeting in Lafayette, Louisiana will be held on March 21, 2006; the public meeting in Galveston, Texas will be held on March 22, 2006; and the public meeting in Corpus Christi, Texas will be held on March 23, 2006. Each public meeting will be held from 5 p.m. to 7 p.m., and will be preceded by an open house from 3 p.m. to 4:30 p.m. The public meeting may end later than the stated time, depending on the number of persons wishing to speak. Material submitted in response to the request for comments must reach the Docket Management Facility on or before April 17, 2006. ADDRESSES: The public meeting and informational open house will be held at: VerDate Aug<31>2005 14:30 Mar 03, 2006 Jkt 208001 Holiday Inn Central, 2032 NE. Evangeline Thruway, Lafayette, LA 70501; telephone 337–233–6815; Galveston Island Convention Center at the San Luis Resort, 5600 Seawall Boulevard, Galveston, TX 77551, telephone 409–763–6564; and Omni Bayfront Tower, 900 North Shoreline Boulevard, Corpus Christi, TX 78401; telephone 361–887–1600. Address docket submissions for USCG– 2005–21232 to: Docket Management Facility, U.S. Department of Transportation, 400 Seventh Street, SW., Washington, DC 20590–0001. The Docket Management Facility accepts hand-delivered submissions, and makes docket contents available for public inspection and copying, at this address, in room PL–401, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The Facility’s telephone is 202–366–9329, its fax is 202–493–2251, and its Web site for electronic submissions or for electronic access to docket contents is https://dms.dot.gov. FOR FURTHER INFORMATION CONTACT: Ray Martin, U.S. Coast Guard, telephone: 202–267–1683, e-mail: rmartin@comdt.uscg.mil. If you have questions on viewing the docket, call Renee V. Wright, Program Manager, Docket Operations, telephone: 202–493– 0402. SUPPLEMENTARY INFORMATION: Public Meeting and Open House We invite you to learn about the proposed deepwater port at the informational open house, and to comment at the public meeting on the proposed action and the evaluation contained in the DEIS. Please notify the Coast Guard (see FOR FURTHER INFORMATION CONTACT) if you wish to speak at the public meeting. In order to allow everyone a chance to speak, we may limit speaker time, or extend the meeting hours, or both. You must identify yourself, and any organization you represent, by name. Your remarks will be recorded or transcribed for inclusion in the public docket. You may submit written material at the public meeting, either in place of or in addition to speaking. Written material must include your name and address, and will be included in the public docket. Public docket materials will be made available to the public on the Docket Management Facility’s Docket Management System (DMS). See ‘‘Request for Comments’’ for information about DMS and your rights under the Privacy Act. PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 If you plan to attend either the open house or the public meeting, and need special assistance such as sign language interpretation or other reasonable accommodation, please notify the Coast Guard (see FOR FURTHER INFORMATION CONTACT) at least 3 business days in advance. Include your contact information as well as information about your specific needs. Request for Comments We request public comments or other relevant information on the DEIS. The public meeting is not the only opportunity you have to comment on the DEIS. In addition to or in place of attending the meeting, you can submit material to the Docket Management Facility during the public comment period (see DATES). The Coast Guard will consider all comments submitted during the public comment period, and then will prepare the final EIS. We will announce the availability of the final EIS and once again give you an opportunity for review and comment. (If you want that notice to be sent to you, please contact the Coast Guard contact person identified in FOR FURTHER INFORMATION CONTACT.) Submissions should include: • Docket number USCG–2005–21232. • Your name and address. • Your reasons for making each comment or for bringing information to our attention. Submit comments or material using only one of the following methods: • Electronic submission to DMS, https://dms.dot.gov. • Fax, mail, or hand delivery to the Docket Management Facility (see ADDRESSES). Faxed or hand delivered submissions must be unbound, no larger than 81⁄2 by 11 inches, and suitable for copying and electronic scanning. If you mail your submission and want to know when it reaches the Facility, include a stamped, self-addressed postcard or envelope. Regardless of the method used for submitting comments or material, all submissions will be posted, without change, to the DMS Web site (https:// dms.dot.gov), and will include any personal information you provide. Therefore, submitting this information makes it public. You may wish to read the Privacy Act notice that is available on the DMS Web site, or the Department of Transportation Privacy Act Statement that appeared in the Federal Register on April 11, 2000 (65 FR 19477). You may view docket submissions at the Docket Management Facility (see ADDRESSES), or electronically on the DMS Web site. SUPPLEMENTARY INFORMATION: E:\FR\FM\06MRN1.SGM 06MRN1

Agencies

[Federal Register Volume 71, Number 43 (Monday, March 6, 2006)]
[Notices]
[Pages 11215-11216]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-2098]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Deoxyhypusine Hydroxylase

Myung Hee Park et al. (NIDCR)

    U.S. Provisional Application No. 60/748,879 filed 09 Dec 2005 (HHS 
Reference No. E-051-2006/0-US-01).
Licensing Contact: John Stansberry; 301/435-5236; 
stansbej@mail.nih.gov.

    Translation initiation factor eIF5A is a highly conserved 
eukaryotic protein. One of its lysine residues is enzymatically 
modified, using spermidine, to form an unusual amino acid, hypusine, a 
posttranslational modification unique to eIF-5A. This eukaryotic 
initiation factor (eIF5A) and its hypusine modification are essential 
for mammalian cell proliferation. Inventors at the National Institutes 
of Health have recently cloned and characterized the enzyme 
deoxyhypusine hydroxylase (DOHH) that catalyzes the final step in the 
modification of eIF5A. The inventors have characterized and cloned both 
the yeast and human recombinant versions of this enzyme.
    Studies have shown that metal chelating compounds like deferiprone 
and ciclopirox olamine that inhibit DOHH activity in cells also inhibit 
HIV-1 replication in cell culture. These findings suggest potential 
utility of DOHH as a novel target for anti-cancer and anti-retroviral 
therapy. These advances could also conceivably lead to the development 
of small molecule inhibitors that bind to specific sites in the enzyme.
    In addition to licensing, the technology is available for further 
development through collaborative research opportunities with the 
inventors.

Methods of Treating Cancer Using Pyridine Carboxaldehyde Pyridine 
Thiosemicarbazone Radiosensitizing Agents

Philip J. Tofilon et al. (NCI)

    U.S. Provisional Application No. 60/718,172 filed 16 Sep 2005 (HHS 
Ref. No. E-319-2005/0-US-01).
Licensing Contact: George G. Pipia; 301/435-5560; pipiag@mail.nih.gov.

    Ribonucleotide reductase is the rate-limiting enzyme of de novo DNA 
synthesis. The enzyme is composed of two homodimer subunits, hRRM1 and 
hRRM2. Hydroxyurea, a ribonucleotide reductase inhibitor, is commonly 
used in conjunction with radiotherapy but it its efficacy as shown in 
many chemoradiation trials is limited. Triapine (2-carboxyaldehyde 
pyridine thiosemicarbazone), a novel ribonucleotide reductase 
inhibitor, exhibits sensitivity to the subunit hRRM2 and inhibits 
ribonucleotide reductase more effectively when compared to hydroxyurea, 
thus imparting a radiosensitizing effect.
    This present invention provides methods of preventing DNA synthesis 
and DNA repair after exposing cells to ionizing radiation. The present 
invention further provides methods of treating cancer and other tumors 
by coadministration of a radiosensitizing amount of Triapine and 
ionizing radiation.

Methods and Compositions for Treating FUS1 Related Disorders

Michael I. Lerman et al. (NCI)
U.S. Provisional Application No. 60/697,596 filed 07 Jul 2005 (HHS 
Reference No. E-137-2005/0-US-01).
Licensing Contact: Thomas Clouse; 301/435-4076; clousetp@mail.nih.gov.

    The FUS1 gene residing in the 3p21.3 chromosome region may function 
as a tumor suppressor gene. Results show that FUS1 null mutants show 
consistent changes in NK cells and secreted antibodies, suggesting that 
FUS1 plays an important role in the development and activation of the 
mammalian immune system. The invention relates to methods, systems and 
transgenic animals useful for screening, diagnosing and treating FUS1 
related disorders. Interestingly, targeted disruption of FUS1 gene in 
mice resulted in a viable and fertile phenotype.
    Possible uses of this invention include using the FUS1 protein to 
modulate and boost the immune system in diseases like cancer and AIDS. 
Also, the cDNA and the corresponding protein are small and the 
applications could include gene therapy with

[[Page 11216]]

appropriate vectors and protein transduction technology.

    Dated: February 28, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 06-2098 Filed 3-3-06; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.